PHARMING GRP SP. ADRS (PHG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PHARMING GRP SP. ADRS (PHG) has a cash flow conversion efficiency ratio of 0.039x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€10.71 Million ≈ $12.52 Million USD) by net assets (€277.10 Million ≈ $323.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of PHARMING GRP SP. ADRS for the company's overall valuation and market capitalisation.
PHARMING GRP SP. ADRS - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how PHARMING GRP SP. ADRS's cash flow conversion efficiency has evolved over time, based on yearly financial data.
PHARMING GRP SP. ADRS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PHARMING GRP SP. ADRS ranked by their cash flow conversion efficiency. Explore PHG cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Changhua Auto Parts Co Ltd
SHG:605018
|
0.048x |
|
Replimune Group Inc
NASDAQ:REPL
|
-0.313x |
|
Beijing Fengshangshiji Culture Medi
SHE:300860
|
0.015x |
|
GMR Power and Urban Infra Limited
NSE:GMRP&UI
|
0.162x |
|
EuroTeleSites AG
F:7YF
|
N/A |
|
Newgen Software Technologies Limited
NSE:NEWGEN
|
0.050x |
|
Metallus, Inc
NYSE:MTUS
|
-0.039x |
|
Shandong Nanshan Zhishang Sci-Tech Co.Ltd.
SHE:300918
|
-0.024x |
Annual Cash Flow Conversion Efficiency for PHARMING GRP SP. ADRS (2021–2025)
The table below shows the annual cash flow conversion efficiency of PHARMING GRP SP. ADRS from 2021 to 2025. View PHARMING GRP SP. ADRS (PHG) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €277.10 Million ≈ $323.96 Million |
€54.71 Million ≈ $63.96 Million |
0.197x | +2531.41% |
| 2024-12-31 | €221.06 Million ≈ $258.44 Million |
€-1.79 Million ≈ $-2.10 Million |
-0.008x | +89.73% |
| 2023-12-31 | €218.78 Million ≈ $255.78 Million |
€-17.30 Million ≈ $-20.23 Million |
-0.079x | -172.06% |
| 2022-12-31 | €204.64 Million ≈ $239.24 Million |
€22.46 Million ≈ $26.26 Million |
0.110x | -44.05% |
| 2021-12-31 | €192.92 Million ≈ $225.54 Million |
€37.84 Million ≈ $44.24 Million |
0.196x | -- |
About PHARMING GRP SP. ADRS
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more